Verbatim response from ChatGPT
Short answer: several routine and a few advanced blood biomarkers are repeatedly linked to all‑cause mortality, cardiovascular disease, and “biological age.” For practical longevity tracking, prioritize metabolic health, lipids/atherosclerotic risk, inflammation, kidney/liver function, blood counts, and a few advanced cardiac/metabolic markers. Below I list the most important markers, why they matter, what direction is generally better, and testing options/brands to consider.
High‑priority (most evidence + actionable)
- HbA1c and fasting glucose (and fasting insulin when available)
- Why: Strong predictors of diabetes, cardiovascular disease, and mortality. Insulin resistance drives many aging pathways.
- Direction: Lower within the normal range (avoid hypoglycemia). Aim to prevent progression to prediabetes/diabetes.
- Standard lipid panel plus ApoB and/or non‑HDL cholesterol
- Why: LDL and non‑HDL predict atherosclerotic cardiovascular disease; ApoB often outperforms LDL as a particle‑based risk measure.
- Direction: Lower LDL/ApoB and non‑HDL are better for CV risk; targets are individualized by risk.
- Lipoprotein(a) — Lp(a)
- Why: Genetic, independent risk factor for atherosclerotic disease and stroke; important to know because it alters treatment decisions.
- Direction: Lp(a) is mostly fixed genetically; knowing level informs prevention.
- High‑sensitivity CRP (hs‑CRP)
- Why: Widely validated inflammation marker predicting cardiovascular events and mortality.
- Direction: Lower is better.
- Kidney function: serum creatinine/eGFR and cystatin C, plus urine albumin:creatinine ratio (UACR)
- Why: Kidney function is a strong predictor of mortality; albuminuria indicates vascular damage.
- Direction: Higher eGFR and no albuminuria are better.
- Complete blood count with RDW and hemoglobin
- Why: Anemia and elevated RDW are robust predictors of mortality in many studies.
- Direction: Normal hemoglobin and lower RDW within normal limits.
- Liver tests, especially GGT/ALT
- Why: GGT and some liver enzymes associate with metabolic dysfunction, oxidative stress and mortality.
- Direction: Lower within the normal range.
Useful / medium priority
- hs‑Troponin and NT‑proBNP
- Why: Very sensitive cardiac biomarkers; predict CV events and death even when patients are asymptomatic.
- Direction: Lower is better; elevations prompt cardiology workup.
- Inflammatory cytokines (IL‑6) and fibrinogen
- Why: Strong links to aging and mortality beyond CRP in research settings.
- Direction: Lower is better; more often used in research/advanced clinics.
- Vitamin D (25‑OH vitamin D)
- Why: Low levels associate with higher mortality and various diseases; deficiency is common and correctable.
- Direction: Avoid deficiency; optimal range debated — discuss with clinician.
- Thyroid function (TSH, free T4)
- Why: Both overt and subtle thyroid dysfunction affect mortality and healthspan.
- Ferritin, iron studies, B12, folate
- Why: Iron overload and deficiency, and B12 deficiency, both have health consequences.
- Homocysteine
- Why: Marker tied to vascular risk; modifiable with B vitamins in deficiency states.
Advanced / research-oriented (consider if you’re doing deep longevity work)
- Apolipoprotein A1 / ApoB ratio, advanced lipid testing (NMR LipoProfile)
- Why: Detailed particle information refines risk stratification.
- GlycA (NMR inflammation measure) and metabolomic panels
- Why: Strong prognostic power in large cohorts (Nightingale Health panels are an example).
- Epigenetic aging clocks (DNA methylation age; e.g., TruDiagnostic)
- Why: Correlate with biological age and respond to interventions in some studies; still evolving.
- Telomere length testing (e.g., Life Length / TeloYears)
- Why: Mixed evidence; interesting but not yet a definitive clinical guide.
- Lp‑PLA2, MPO, other specialized vascular markers — center/clinic dependent.
How to use these results
- Start with baseline panel: fasting glucose/HbA1c, fasting lipid panel + ApoB or non‑HDL, hs‑CRP, CMP (kidney/liver), CBC (with RDW), vitamin D, TSH, urine ACR.
- If atherosclerotic risk is a concern: add Lp(a), ApoB, NMR lipoprofile, hs‑troponin/NT‑proBNP.
- If you want deep profiling: consider metabolomics (Nightingale), epigenetic clocks (TruDiagnostic), or telomere testing — but treat them as research/monitoring tools, not definitive clinical decisions.
What changes longevity when these are out of range
- Most markers reflect risk pathways you can modify: control blood sugar, lower atherogenic lipids (diet, exercise, statins/medication as indicated), reduce chronic inflammation (smoking cessation, weight loss, exercise, sleep, diet), treat vitamin deficiencies, control blood pressure, and address kidney/liver disease early.
Where to get tested (brands/services)
- Standard clinical labs: Quest Diagnostics, LabCorp — reliable for basic and many advanced tests (Lp(a), ApoB, hs‑CRP, NMR LipoProfile via LabCorp).
- Hospital/health system labs: your primary care provider can order validated tests and interpret in clinical context.
- Longevity/wellness services:
- InsideTracker — combines clinical labs with lifestyle recommendations geared to performance/longevity.
- TruDiagnostic — focused on epigenetic aging (DNA methylation clocks).
- Nightingale Health — large-scale metabolomics and NMR‑based biomarker panels used in research and personalized reports.
- Cleveland HeartLab — advanced cardiovascular risk and inflammation testing.
- At‑home kits (screening, not diagnostic): Everlywell, LetsGetChecked, HealthLabs offer convenience for basic panels; abnormal results should be followed up with a clinician.
Caveats and practical advice
- Many biomarkers are interrelated; treat the person, not a single number. Clinical context and trends over time matter more than one isolated result.
- Some advanced tests (epigenetic clocks, telomere length, certain metabolomics) are interesting but still emerging; use them to guide lifestyle changes rather than for diagnoses.
- Discuss abnormal results and treatment options with your clinician before starting supplements or medications.
- Frequency: baseline, then repeat annually or more often if abnormalities are present or if you start therapies.
If you want, tell me your age, sex, family history (especially early heart disease), and whether you want a simple starter panel or a deep longevity profile — I can suggest a specific test list and which labs/services would be best for that plan.